Gilead Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gilead Sciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 17.3 times. Higher than 96% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 8% in 3 years; of every extra $100 of sales, $181 became extra profit. Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$197Over the last 3 years, every $100 of reported profit came with $197 of operating cash.
Higher than 76% of Healthcare companies in United States.
Self-Funding Ratio
17.3×Over the last 3 years its own operating cash covered its investment spending (capex) 17.3 times.
Higher than 96% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $16 tied up three years earlier.
Less money tied up than 58% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$181Sales grew 8% in 3 years; of every extra $100 of sales, $181 became extra profit.
Higher than 87% of Healthcare companies in United States.
Asset Productivity Ratio
+8% / -7%In 3 years sales changed by +8% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
3.6×Debt due within a year is covered 3.6 times by its yearly operating cash.
Higher than 78% of Healthcare companies in United States.
Cash Cushion Ratio
−8%Debt, after subtracting cash, equals 8% of its market value (net debt).
Lower than 77% of Healthcare companies in United States.
Tangible Assets Ratio
57%Of every $100 the company owns, $57 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 72% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 76% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Gilead Sciences, Inc. made a loss over the last year. Gilead Sciences, Inc. owes $0.76 for every $1 it owns. Net profit rose 1673% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGilead Sciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
16.48The share price is 16.48 times Gilead Sciences, Inc.'s book value per share, higher than 92% of Healthcare companies in United States.
Market cap
$194.9 BThe total market value of all of Gilead Sciences, Inc.'s shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$11.8 BWhat Gilead Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.54Net worth divided by the number of shares. The share price of $157.19 is 16.5 times this, which is the P/B above.
Return on equity (ROE)
-20.7%Gilead Sciences, Inc. lost 20.7% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.76×Gilead Sciences, Inc. owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
2.14%Gilead Sciences, Inc. pays 2.14% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in United States.
Revenue growth
+2%Revenue rose 2% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
+1673%Net profit rose 1673% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Profit margin
28.9%Gilead Sciences, Inc. keeps $29 of every $100 of revenue as net profit.
Cash quality
1.2×Cash from Gilead Sciences, Inc.'s business was 1.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
11.4×Gilead Sciences, Inc.'s operating profit covered its interest costs 11.4 times in the year to Dec 2025.
Cash vs debt
Net debtGilead Sciences, Inc. had $15.3 B more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gilead Sciences, Inc.: $194.9 B ÷ $11.8 B (30 Jun 2026) = 16.5.
What is Gilead Sciences, Inc.'s return on equity?
Gilead Sciences, Inc. lost 20.7% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does Gilead Sciences, Inc. owe compared with what it owns?
Gilead Sciences, Inc. owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does Gilead Sciences, Inc. pay a dividend?
Yes. Gilead Sciences, Inc. pays 2.14% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in United States.
Is Gilead Sciences, Inc.'s revenue growing?
Revenue rose 2% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.